Genscript Biotech (HK:1548) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Genscript Biotech Corporation has announced the approval of a New Drug Application by China’s National Medical Products Administration for ciltacabtagene autoleucel, a therapy for relapsed or refractory multiple myeloma. This significant development is expected to draw the attention of shareholders and potential investors, who are advised to consider investment risks carefully. The drug, developed by an indirect non-wholly owned subsidiary, marks a notable advancement in the treatment of this challenging medical condition.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
